RE: Cizzle19 Dec 2022 08:05
''Dr. David Tapolczay, CEO Conduit, commented: "I am pleased to agree the Option with Cizzle, following the exercise of which Conduit will acquire Cizzle's interest in the AZD1656 therapeutic assets with potential applications in inflammatory pulmonary and cardiovascular disease, which is part of Conduit's strategy to maximise its economic interest in each indication of AZD1656 we intend to focus on developing in 2023."''